Overview

Abiraterone Post Ketoconazole for Prostate Cancer

Status:
Completed

Trial end date:
2016-03-14

Target enrollment:

Participant gender:

Summary

This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on ketoconazole. It is hypothesized that abiraterone will be active in patients who have experienced disease progression on ketoconazole

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Collaborators:

Cougar Biotechnology, Inc.
Johnson & Johnson

Treatments:

Abiraterone Acetate
Ketoconazole